Known targets — ChEMBL curated mechanism
GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BM
The experimentally established mechanism targets of Amantadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 known ✓ | Q05586 | 6/20 | 0.93 |
| ▸ | GRIN2A known ✓ | Q12879 | 6/20 | 0.93 |
| ▸ | GRIN2D known ✓ | O15399 | 5/20 | 0.93 |
| ▸ | GRIN3B known ✓ | O60391 | 5/20 | 0.93 |
| ▸ | GRIN2B known ✓ | Q13224 | 5/20 | 0.93 |
| ▸ | GRIN2C known ✓ | Q14957 | 5/20 | 0.93 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 5/20 | 0.93 |
| ▸ | LMNA | P02545 | 4/20 | 0.93 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.93 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.93 |
| ▸ | SLC22A2 | O15244 | 2/20 | 0.93 |
| ▸ | SLC47A1 | Q96FL8 | 2/20 | 0.93 |
| ▸ | TSHR | P16473 | 1/20 | 0.93 |
| ▸ | STAT6 | P42226 | 1/20 | 0.93 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.93 |
| ▸ | THRB | P10828 | 2/20 | 0.87 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.87 |
| ▸ | POLB | P06746 | 1/20 | 0.87 |
| ▸ | BLM | P54132 | 1/20 | 0.87 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amantadine SCHEMBL28246033 | 0.97 | GRIN1 (0.87) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Amantadine SCHEMBL4098 | 0.96 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Amantadine SCHEMBL21309814 | 0.96 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Amantadine SCHEMBL21310017 | 0.96 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Amantadine SCHEMBL15532073 | 0.96 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Amantadine SCHEMBL20409394 | 0.96 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Amantadine SCHEMBL3642447 | 0.96 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Amantadine SCHEMBL15672299 | 0.96 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Amantadine SCHEMBL23859927 | 0.93 | GRIN1 (0.93) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Amantadine SCHEMBL21192810 | 0.93 | GRIN1 (0.93) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114007571-B | Dental composition | 登士柏德特里有限公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-4076336-B1 | DENTAL ROOT CANAL FILLING COMPOSITION | DENTSPLY DETREY GMBH (DE) | 2024-05-15 | — | — | EP | disclosed |
| CN-114929178-A | Dental root canal filling composition | 登士柏德萃有限公司 | 2022-08-19 | — | — | CN | disclosed |
| US-20220175623-A1 | DENTAL COMPOSITION | DENTSPLY SIRONA INC. (US) | 2022-06-09 | — | — | US | disclosed |
| EP-3952820-A1 | DENTAL COMPOSITION | DENTSPLY DETREY GmbH (DE) | 2022-02-16 | — | — | EP | disclosed |
| CN-114007571-A | Dental composition | 登士柏德特里有限公司 | 2022-02-01 | — | — | CN | disclosed |
| WO-2021122957-A1 | DENTAL ROOT CANAL FILLING COMPOSITION | DENTSPLY DETREY GMBH (DE) | 2021-06-24 | — | — | WO | disclosed |
| WO-2020208148-A1 | DENTAL COMPOSITION | DENTSPLY DETREY GMBH (DE) | 2020-10-15 | — | — | WO | disclosed |
| EP-3721857-A1 | DENTAL COMPOSITION | Dentsply DeTrey GmbH (DE) | 2020-10-14 | — | — | EP | disclosed |
| US-10245326-B2 | Amantadine, memantine, and rimantadine conjugates and a pharmaceutical composition for treatment of neuronal disorders | MILLER LANDON C G (US) | 2019-04-02 | — | — | US | disclosed |
| CN-105399636-A | Process for preparation of amantadine free amine amantadine by use of amantadine hydrochloride | TIANJIN MINXIANG BIOPHARMACEUTICAL CO LTD | 2016-03-16 | — | — | CN | disclosed |
| CN-102293764-B | New application of p-hydroxycinnamic acid | UNIV CHINA AGRICULTURAL | 2013-06-26 | — | — | CN | disclosed |
| US-20130019572-A1 | SYSTEM FOR THE STABILIZATION, CONSERVATION AND STORAGE OF NUCLEIC ACID | STRATEC MOLECULAR AG (DE) | 2013-01-24 | — | — | US | disclosed |
| CN-102293764-A | New application of p-hydroxycinnamic acid | — | 2011-12-28 | — | — | CN | disclosed |
| CN-101780064-B | Application of p-hydroxycinnamic acid | UNIV CHINA AGRICULTURAL | 2011-10-05 | — | — | CN | disclosed |
| CN-101780064-A | New application of p-hydroxycinnamic acid | UNIV CHINA AGRICULTURAL | 2010-07-21 | — | — | CN | disclosed |
| EP-1638931-A4 | METHOD OF TARGETING A THERAPEUTIC AGENT | NEUROMOLECULAR INC (US) | 2007-11-07 | — | — | EP | disclosed |
| EP-1638931-A2 | METHOD OF TARGETING A THERAPEUTIC AGENT | Neuromolecular Inc. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050124701-A1 | Method of targeting a therapeutic agent | NEUROMOLECULAR, INC. | 2005-06-09 | — | — | US | disclosed |
| WO-2005019166-A2 | METHOD OF TARGETING A THERAPEUTIC AGENT | NEUROMOLECULAR, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175623-A1 | DENTAL COMPOSITION | PHOSPHO1, GPX4, CYP24A1 | GRIN1 2439/4885GRIN2A 1733/4885GRIN2D 1115/4885 |
| US-20050124701-A1 | Method of targeting a therapeutic agent | GAP43, CHAT, NEFM | GRIN1 96/4885GRIN2A 16/4885GRIN2D 157/4885 |
| US-10245326-B2 | Amantadine, memantine, and rimantadine conjugates and a pharmaceutical composition for treatment of neuronal disorders | NTSR1, GALR2, NTSR2 | GRIN1 126/4885GRIN2A 87/4885GRIN2D 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.